MARKET

PTHS

PTHS

Pelthos Therapeutics
AMEX
20.40
-0.90
-4.23%
After Hours: 20.40 0 0.00% 16:10 04/02 EDT
OPEN
20.40
PREV CLOSE
21.30
HIGH
21.35
LOW
20.40
VOLUME
10.04K
TURNOVER
--
52 WEEK HIGH
54.29
52 WEEK LOW
9.00
MARKET CAP
68.45M
P/E (TTM)
-0.8856
1D
5D
1M
3M
1Y
5Y
1D
Cantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight Recommendation
NASDAQ · 1d ago
Pelthos Therapeutics Price Target Announced at $50.00/Share by Cantor Fitzgerald
Dow Jones · 2d ago
Pelthos Therapeutics Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 2d ago
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 2d ago
Pelthos Therapeutics doses first patient in CT2000 trial
TipRanks · 3d ago
Pelthos Therapeutics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Evaluating CT2000 As Potential Treatment For Eye Pain
Benzinga · 3d ago
Alliance Global Partners Keeps Their Buy Rating on Pelthos Therapeutics (PTHS)
TipRanks · 4d ago
Weekly Report: what happened at PTHS last week (0323-0327)?
Weekly Report · 4d ago
More
About PTHS
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.

Webull offers Pelthos Therapeutics Inc stock information, including AMEX: PTHS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTHS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTHS stock methods without spending real money on the virtual paper trading platform.